ELUVIA™

Drug-Eluting Vascular Stent System

Restenosis in the SFA

A harsh SFA environment
Significant mechanical forces in the SFA prolong the response to injury and make the SFA susceptible to restenosis.

Sign-up for Newsletter
sales-rep.png

Request a Sales Representative

 icon-send-questions.png

Submit your question

 icon_document.png

Sign up for DET Case Studies

 icon-educare-cta.png

Learn on Educare
Clinical History of Restenosis
Iida, O. et al. Catheterization and Cardiovascular Interventions. 2011; 78:611–617.

 

Restenosis following nitinol stenting peaks at about 12 months in the SFA.

SUSTEND™ Drug-Delivery Technology

The Eluvia™ Stent, with Sustend™ drug-delivery technology, is designed to deliver paclitaxel when restenosis is most likely to occur.

Polymer-based technology with proven biocompatibility1

  •  Implanted in more than 10 million vessels since 2007
  •  More than 20,000 patients studied in clinical trials
DRUG TISSUE CONCENTRATIONS OVER TIME
*Based on pre-clinical PK analysis. Data on file at Boston Scientific. Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610.

 

More than 12 months of sustained drug release

Built on the Innova™ Stent platform, designed to provide uniform scaffolding for drug delivery while optimizing:

  •  Flexibility
  •  Radial strength
  •  Fracture resistance
Learn more about the stent platform
Eluvia Stent designed for flexibility, radial strength, fracture resistance
Top